Atripla which made by Bristol-Myers-Squibb and Gilead Sciences, contains efavirenz, tenofovir and emtricitabine. It is the first "one-a-day" HAART treatment for HIV-infected patients. Thus, patients should be more compliant in the use of their medications and, it is hoped, that this will result in a lowered risk of the emergence of resistant HIV mutants. The drug combination will still be very expensive (over $10,000 per year).

June 2006